Reference:
FLCCC Alliance. (2021). I-MASK+ protocol: Prevention and early outpatient treatment protocol for COVID-19 (Version 18). Retrieved from https://www.flccc.net/covid-19-protocols
Summary:
The I-MASK+ protocol, developed by the Front Line COVID-19 Critical Care Alliance (FLCCC), is designed for the prevention and early outpatient treatment of COVID-19, particularly against the Delta variant. It emphasises the use of ivermectin as a primary agent due to its antiviral and anti-inflammatory properties, supported by extensive clinical trial data. The protocol recommends dosing guidelines for ivermectin in both chronic prevention and post-exposure scenarios, alongside other supportive medications such as Vitamin D, Vitamin C, and zinc. Additionally, the protocol outlines preventive measures like social distancing, hand hygiene, and mask-wearing. Importantly, it is not a substitute for vaccination but serves as a complementary strategy. The document also highlights the role of dual anti-androgen therapy and corticosteroids for more severe cases. The efficacy of the protocol is further endorsed by successful outcomes in regions like Uttar Pradesh, India, where widespread ivermectin distribution has led to significant reductions in COVID-19 incidence. Continuous updates are encouraged in response to emerging scientific evidence, ensuring the protocol remains relevant and effective in combating COVID-19. This summary provides a comprehensive insight into the I-MASK+ protocol, which combines various therapeutic agents and preventive strategies aimed at managing COVID-19 effectively.